Brief #10296Updated 18 NOV 2025ALAMEDAMENLO VENTURESSERIES B
Employbl DossierScribe Therapeutics
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
- Founded
- 2017
- Headcount
- 101
- Open roles
- 0
- Last raised
- Series B · $100M
Section II · Premium ProfileMembers only
- 01Engineering interview process at Scribe TherapeuticsLocked
- 02Tech stack & infrastructure choicesLocked
- 03Culture & day-to-day work styleLocked
- 04Why join now vs. 6 months from nowLocked
- 05Hiring focus & open headcount by teamLocked
- 06Comp philosophy and band contextLocked
7-day free trial · $25/mo · cancel anytime
